Your browser is no longer supported. Please, upgrade your browser.
FibroGen, Inc.
Index- P/E- EPS (ttm)-2.62 Insider Own1.00% Shs Outstand90.56M Perf Week-3.90%
Market Cap4.58B Forward P/E- EPS next Y-0.82 Insider Trans-6.33% Shs Float83.64M Perf Month1.50%
Income-228.80M PEG- EPS next Q-0.24 Inst Own80.30% Short Float7.53% Perf Quarter21.05%
Sales119.30M P/S38.38 EPS this Y13.60% Inst Trans4.54% Short Ratio8.83 Perf Half Y20.47%
Book/sh4.99 P/B10.03 EPS next Y51.80% ROA-27.70% Target Price62.33 Perf Year23.35%
Cash/sh7.52 P/C6.66 EPS next 5Y- ROE-50.20% 52W Range22.65 - 57.21 Perf YTD34.89%
Dividend- P/FCF113.06 EPS past 5Y22.50% ROI-15.30% 52W High-12.55% Beta1.36
Dividend %- Quick Ratio6.10 Sales past 5Y13.30% Gross Margin94.00% 52W Low120.88% ATR2.45
Employees531 Current Ratio6.20 Sales Q/Q32.50% Oper. Margin- RSI (14)50.16 Volatility5.41% 4.77%
OptionableYes Debt/Eq0.13 EPS Q/Q162.00% Profit Margin- Rel Volume0.91 Prev Close49.86
ShortableYes LT Debt/Eq0.10 EarningsMar 01 AMC Payout- Avg Volume713.33K Price50.03
Recom2.20 SMA20-3.30% SMA509.34% SMA20017.54% Volume646,967 Change0.34%
Feb-01-21Initiated H.C. Wainwright Buy $58
Oct-26-20Initiated Raymond James Underperform
Jul-10-20Resumed Stifel Buy $71
May-01-20Initiated Cowen Market Perform $40
Apr-27-20Initiated BofA/Merrill Neutral $45
May-29-19Resumed Goldman Neutral
May-10-19Downgrade William Blair Outperform → Mkt Perform
Apr-12-19Initiated Piper Jaffray Neutral $65
Feb-11-19Resumed Stifel Buy $71
Dec-19-18Upgrade Citigroup Neutral → Buy
Aug-08-17Reiterated Stifel Buy $38 → $80
Aug-08-17Reiterated Leerink Partners Outperform $52 → $82
Jul-21-17Downgrade Goldman Buy → Neutral
Jul-11-17Initiated Jefferies Buy
Feb-11-16Upgrade Credit Suisse Neutral → Outperform $40
Jan-21-16Initiated Credit Suisse Neutral
Dec-04-15Initiated Citigroup Buy
Sep-23-15Initiated Lake Street Hold $25
Jul-29-15Initiated Citigroup Buy $37
Jul-20-15Upgrade Goldman Neutral → Buy
Feb-21-21 02:52AM  
Feb-18-21 07:00AM  
Feb-12-21 07:00AM  
Dec-23-20 01:16AM  
Dec-22-20 07:00AM  
Dec-21-20 06:46PM  
Dec-18-20 04:59PM  
Dec-02-20 07:00AM  
Dec-01-20 08:00AM  
Nov-30-20 01:39PM  
Nov-29-20 07:03AM  
Nov-27-20 07:00AM  
Nov-08-20 07:46AM  
Nov-06-20 03:30PM  
Nov-05-20 06:15PM  
Nov-03-20 08:31AM  
Oct-30-20 09:02AM  
Oct-29-20 07:00AM  
Oct-22-20 10:08AM  
Oct-14-20 07:00AM  
Oct-02-20 07:00AM  
Sep-29-20 05:22PM  
Sep-15-20 07:31AM  
Sep-08-20 07:00AM  
Sep-04-20 07:28AM  
Sep-01-20 07:00AM  
Aug-11-20 07:00AM  
Aug-06-20 08:10PM  
Jul-30-20 12:33PM  
Jul-24-20 09:35AM  
Jul-23-20 07:00AM  
Jul-17-20 03:31PM  
Jun-24-20 12:00PM  
Jun-23-20 04:05PM  
Jun-22-20 07:00AM  
Jun-16-20 09:20AM  
Jun-15-20 10:42AM  
Jun-10-20 08:37PM  
Jun-09-20 10:17AM  
Jun-08-20 05:00PM  
May-27-20 07:00AM  
May-21-20 07:00AM  
May-20-20 10:00PM  
May-11-20 06:32AM  
May-09-20 05:01PM  
May-08-20 07:00AM  
May-07-20 08:40PM  
May-06-20 08:43AM  
May-03-20 10:17AM  
Apr-30-20 12:33PM  
Apr-24-20 07:00AM  
Apr-21-20 05:31PM  
Apr-20-20 07:00AM  
Mar-27-20 02:52PM  
Mar-24-20 04:23PM  
Mar-04-20 07:07AM  
Mar-03-20 08:13PM  
Mar-02-20 05:15PM  
Feb-24-20 12:30PM  
Feb-18-20 07:00AM  
Feb-12-20 09:45AM  
Feb-11-20 05:00PM  
Feb-03-20 03:42PM  
Jan-31-20 09:12AM  
Jan-30-20 12:01AM  
Jan-13-20 05:59PM  
Jan-06-20 06:03PM  
Dec-24-19 08:55AM  
Dec-23-19 05:42PM  
Dec-17-19 06:45AM  
Dec-06-19 10:03AM  
Dec-02-19 07:00AM  
Nov-15-19 02:20PM  
Nov-14-19 07:42PM  
Nov-13-19 08:03PM  
Nov-11-19 05:15PM  
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kurkijarvi KaleviDirectorFeb 17Option Exercise28.656,000171,90039,100Feb 19 07:10 PM
Kurkijarvi KaleviDirectorFeb 17Sale52.406,000314,38333,100Feb 19 07:10 PM
Kurkijarvi KaleviDirectorJan 19Option Exercise19.056,000114,30039,100Jan 21 07:24 PM
Kurkijarvi KaleviDirectorJan 19Sale43.386,000260,28033,100Jan 21 07:24 PM
Kurkijarvi KaleviDirectorJan 14Option Exercise19.055,999114,28139,099Jan 15 08:02 PM
Kurkijarvi KaleviDirectorJan 14Sale40.045,999240,20033,100Jan 15 08:02 PM
Schoeneck James ADirectorJan 04Option Exercise9.786,00058,65015,400Jan 06 07:08 PM
Kurkijarvi KaleviDirectorDec 28Option Exercise18.346,001110,05939,101Dec 30 06:07 PM
Kurkijarvi KaleviDirectorDec 28Sale40.406,001242,45533,100Dec 30 06:07 PM
Yu K PeonyChief Medical OfficerDec 16Sale41.613,350139,394192,292Dec 17 07:06 PM
Cotroneo PatSVP, Finance and CFODec 15Sale43.603,068133,765266,144Dec 17 07:04 PM
Kouchakji EliasSVP, Clinical Dev, Drug SafetyNov 17Option Exercise14.587,082103,220134,495Nov 19 04:52 PM
Yu K PeonyChief Medical OfficerSep 16Sale44.013,351147,478198,934Sep 18 05:19 PM
Cotroneo PatSVP, Finance and CFOSep 15Sale43.633,070133,944272,226Sep 17 06:03 PM
Yu K PeonyChief Medical OfficerSep 03Option Exercise18.0010,000180,000215,576Sep 04 04:33 PM
Cotroneo PatSVP, Finance and CFOSep 03Option Exercise23.3015,004349,582293,314Sep 04 04:30 PM
Yu K PeonyChief Medical OfficerSep 03Sale50.8910,000508,900205,576Sep 04 04:33 PM
Cotroneo PatSVP, Finance and CFOSep 03Sale50.9115,004763,854278,310Sep 04 04:30 PM
Schoeneck James ADirectorAug 20Option Exercise5.956,00035,70015,400Aug 21 05:58 PM
Cotroneo PatSVP, Finance and CFOAug 11Option Exercise18.727,250135,713278,310Aug 11 04:34 PM
Cotroneo PatSVP, Finance and CFOAug 07Option Exercise19.3922,554437,322293,614Aug 11 04:34 PM
Cotroneo PatSVP, Finance and CFOAug 07Sale48.0022,5541,082,592271,060Aug 11 04:34 PM
Yu K PeonyChief Medical OfficerJul 24Sale42.353,351141,915205,576Jul 28 07:33 PM
Cotroneo PatSVP, Finance and CFOJun 16Sale39.683,928155,863271,060Jun 18 06:35 PM
Conterno Enrique AChief Executive OfficerJun 11Buy35.2819,800698,59927,800Jun 12 06:59 AM
Conterno Enrique AChief Executive OfficerJun 10Buy36.298,000290,2828,000Jun 12 06:59 AM
Rosenkranz Roberto PedroDirectorJun 09Option Exercise23.8524,000572,40096,100Jun 11 09:22 PM
Chung ChristineSVP, China OperationsMar 19Option Exercise25.407,345186,563166,358Mar 19 07:55 PM
KEARNS THOMAS F JRDirectorMar 19Option Exercise2.9018,00052,200161,464Mar 23 05:37 PM
KEARNS THOMAS F JRDirectorMar 19Sale23.1718,000417,074143,464Mar 23 05:37 PM
Chung ChristineSVP, China OperationsMar 19Sale25.917,345190,282159,013Mar 19 07:55 PM
Chung ChristineSVP, China OperationsMar 18Option Exercise25.4040010,160162,918Mar 19 07:55 PM
Chung ChristineSVP, China OperationsMar 18Sale24.793,90596,799159,013Mar 19 07:55 PM
Yu K PeonyChief Medical OfficerMar 16Option Exercise19.393,75072,713166,541Mar 18 08:05 PM
Cotroneo PatSVP, Finance and CFOMar 16Sale26.369,239243,540236,466Mar 18 08:00 PM